Hospital medicine (London, England : 1998) 2003-06-01

Leuprorelin: a leading role in advanced prostate cancer therapy.

Raj Persad

Index: Hosp. Med. 64(6) , 360-3, (2003)

Full Text: HTML

Abstract

Leuprorelin is a luteinizing hormone-releasing hormone analogue, licensed in the UK for the treatment of advanced prostate cancer. This review highlights the efficacy and tolerance of this agent and the benefits provided for developing patient-centred therapy and optimizing patient quality of life.